Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2

(2012) H. Greulich et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas

(2011) Meghan L. Rudd et al.   CLINICAL CANCER RESEARCH

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

(2011) Davide Torti et al.   EMBO Molecular Medicine

International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment

(2010) S. Dawood et al.   ANNALS OF ONCOLOGY

Inflammatory Breast Cancer: The Disease, the Biology, the Treatment

(2010) Fredika M. Robertson et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST